04/7/2020 A CDCN-funded study led by Wenbin Xiao was recently published in Oncogene that identifies two different genetic mutations, MEK2 and RUNX1, that may have contributed to iMCD-TAFRO in one patient each. More research is needed to study these genes in a larger number of patients and explore inhibition of the MAPK pathway as a therapy for iMCD-TAFRO.
This is an exciting first step towards a better understanding of a genetic component to Castleman disease and to iMCD-TAFRO specifically.